Jul 15, 2019 / 12:00PM GMT
Operator
Good morning and welcome to Synlogic's conference call to discuss this morning's announcement of data from its SYNB1618 Phase I/IIa clinical trial. (Operator Instructions) Please be advised that this call is being recorded at Synlogic's request.
I would now like to turn the call over to Dr. Elizabeth Wolffe, Head of Investor Relations and Corporate Communications. You may begin.
Elizabeth Wolffe - Synlogic, Inc. - Head of IR & Corporate Communications
Thank you, Katherine, and good morning, everyone. This morning, we issued a press release outlining top line data from patient cohorts enrolled in our Phase I/IIa clinical trials SYNB1618. Our press release can be found in the Investors and Media section of our website. As we talk about these data in our plans for the next stage of clinical development in more detail, I'd like to take a moment to point you to the slide presentation that accompanies this call, which can also be found on our website. Joining me on the call today is Aoife Brennan, Synlogic's President and Chief Executive Officer; also
Synlogic Inc Corporate Update Transcript
Jul 15, 2019
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers